Aquestive Therapeutics, Inc. - Common Stock (AQST)
5.7900
+0.0100 (0.17%)
NASDAQ · Last Trade: Nov 25th, 9:51 AM EST
Detailed Quote
Previous Close
5.780
Open
5.800
Bid
5.770
Ask
5.810
Day's Range
5.730 - 5.870
52 Week Range
2.120 - 7.550
Volume
128,921
Market Cap
225.15M
PE Ratio (TTM)
-8.155
EPS (TTM)
-0.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,911,199
Chart
About Aquestive Therapeutics, Inc. - Common Stock (AQST)
Aquestive Therapeutics Inc is a biopharmaceutical company dedicated to developing innovative drug therapies that meet unmet medical needs. The company focuses on creating enhanced formulations of approved drugs using its proprietary technology platforms, aiming to provide better patient outcomes through improved delivery methods. With a portfolio that includes treatments for various conditions, particularly those affecting patients with difficulties in swallowing or absorption, Aquestive is committed to advancing therapeutic options that are both effective and patient-friendly. Their efforts are centered around ensuring that patients have access to medications that can significantly improve their quality of life. Read More
WARREN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the upcoming Piper Sandler 37th Annual Healthcare Conference December 2-4, 2025, in New York City.
WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the third quarter ended September 30, 2025 and provided a strategic business update.
WARREN, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced changes to its leadership team to support the launch of Anaphylm™, if approved by the United Stated Food and Drug Administration (FDA), and expansion of its pipeline.
WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that David Amsellem, Sr. Research Analyst at Piper Sandler, will host a live fireside chat with the Company’s management team on November 6, 2025 at 12:00 p.m. ET.
WARREN, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple presentations highlighting results from the investigational use of its product candidate Anaphylm™ (dibutepinephrine) sublingual film in the treatment of severe allergic reactions, including anaphylaxis, will be featured at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting. The meeting will take place November 6-10, 2025, in Orlando, FL.
WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2025 and provide an update on recent developments in its business after market close on Wednesday, November 5, 2025.
WARREN, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the United States Patent and Trademark Office (USPTO) has issued two additional U.S. patents related to Anaphylm, the Company’s novel epinephrine prodrug sublingual film.
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.
Aquestive's Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decision date without panel review.
WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that an advisory committee meeting is not required for Anaphylm™ (dibutepinephrine) Sublingual Film. The Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm remains January 31, 2026.
WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in three upcoming investor conferences in September 2025 as follows:
